Medical Research News
Focus on the latest clinical studies, reports, findings, programs and standards covering a wide spectrum of medical and health issues. This section highlights research into human populations and includes information about research facilities, funding, resources and public policy.
Hinsdale Foot & Ankle Specialist in Hinsdale Now Offering Stem Cell Recruitment Therapy to Help Patients with Foot & Ankle Pain
Hinsdale Foot & Ankle Specialist, is now offering stem cell recruitment therapy to help patients with foot and ankle pain. The regenerative medicine treatments are offered by Dr. Kevin Salvino, a Board Certified Doctor of Podiatric Medicine by the American Board of Podiatric Surgery and an Associate of the American College of Foot and Ankle Surgeons. - March 10, 2016 - Hinsdale Foot & Ankle Specialist
Patricia A. Cleary Recognized as a Professional of the Year for Three Consecutive Years by Strathmore's Who's Who Worldwide Publication
Patricia A. Cleary of Arlington, Virginia has been recognized as a Professional of the Year for three consecutive years by Strathmore’s Who’s Who Worldwide Edition for her outstanding contributions and achievements in the field of education. About Patricia A. Cleary Ms. Cleary has 50... - March 01, 2016 - Strathmore Worldwide
Tryten Debuts NOVA 2 Modular Medical Tablet Cart at HIMSS16
Tryten will be debuting the NOVA 2 Modular Medical Tablet Cart at HIMSS16 booth 12317. - February 29, 2016 - Tryten
Dr. Edward Paul Presents Macular Degeneration Update at Harvard
Seventy-four percent of Americans did not know that age-related macular degeneration (AMD) is the leading cause of blindness in people in the United States over the age of 60, according to a new survey. The top choice selected was, incorrectly, glaucoma. Despite the high prevalence of AMD, the... - February 28, 2016 - Paul Vision Institute
Recursion Pharmaceuticals Supports White House Precision Medicine Initiative
Recursion Pharmaceuticals today announced that it is part of a group of nationally recognized private and public institutions making commitments as part of President Obama's Precision Medicine Initiative to rapidly find new treatments for ultra-rare genetic diseases. - February 25, 2016 - Recursion Pharmaceuticals
SMi’s 16th Annual Pain Therapeutics Meeting to Feature Key Updates from UCL on Translational Biomarkers Following Recent Clinical Breakthrough
University College London Provide a Special Address on Translational Biomarkers for Studying Peripheral Nerves Following Study on Linking Stress Protein and Chronic Pain in Mice. - February 25, 2016 - SAE Media Group
MR Solutions Brings New 3D, 1000X Magnification Imaging Modality to Preclinical Research
MR Solutions’ new 3D in vivo confocal microscope for use in preclinical research provides a magnification range of up to 1000 times, allowing researchers to examine cellular details within a live small animal eliminating the need for a surgical biopsy - saving time and substantially reducing costs. - February 24, 2016 - MR Solutions
ALPCO's New NT-proBNP ELISA Offers Cost Savings and Flexibility
ALPCO recently announced the release of its new NT-proBNP (1-76) ELISA, offering researchers investigating cardiovascular disease, kidney disease, and diabetes with a flexible, user friendly and cost effective tool. The assay is highly characterized to measure changes in levels of NT-proBNP, and... - February 23, 2016 - ALPCO
DogsBite.org Releases 2015 Dog Bite Fatality Statistics; Percentage of Deaths Attributed to Pit Bulls Rises to 82% and Other Trends
In 2015, canines killed 34 Americans. Pit bulls and their mixes contributed to 82% (28) of these deaths, the highest fatality count on record for the breed and the highest percentage in the nonprofit's 11-years of data collection. - February 19, 2016 - DogsBite.org Incorporated
ALPCO Releases New Basophil Activation Test Validated for the Evaluation of Kinase Inhibitors in Early Drug Development
ALPCO has released its new InhibiScreen Basophil Activation Test (BAT) which was developed and validated specifically for the evaluation of kinase inhibitors during early drug development. - February 16, 2016 - ALPCO
F1000Workspace Integrates with Google Docs to Make It Easier for Scientists to Write Papers and Grants
F1000Workspace – a platform that enables scientists to collect, write and discuss scientific literature – has added an innovative new piece of software to its portfolio to help scientists write papers and grants more efficiently. - February 14, 2016 - Faculty of 1000
Real Endpoints’ RxScorecard™ Predicted Launch Failure of Major New Anti-Cholesterol Drugs
Analysis from 2015 showed that because PCSK9 inhibitors had not proved more than incremental value for most patients, payers would dramatically restrict their usage. Poor Q4 sales show that’s exactly what happened. - February 12, 2016 - Real Endpoints
Jared Cumming, Merck, to Give a Presentation at GTCbio’s Protease Inhibitors Conference
Jared Cumming from Merck will discuss, “Discovery of Verubecestat (MK-8931): A beta-Secretase Inhibitor in Phase 3 Clinical Development for Alzheimer’s Disease.” - February 11, 2016 - GTCbio
Assessment Shows Nation’s Guard is Down Against Zika Virus and Mosquito-Borne Diseases
The Council of State and Territorial Epidemiologists (CSTE) supports President Barack Obama’s request of $1.8 billion to combat Zika virus. Declared a “global health emergency” by the World Health Organization, Zika virus increasingly threatens to spread local epidemics in the... - February 08, 2016 - Council of State and Territorial Epidemiologists
NanoCellect Closes $1.75M Series A Financing Round to Begin Production of the WOLF Cell Sorter
NanoCellect Biomedical, a developer of affordable and accessible flow cytometry and cell sorting technology for life sciences, will begin production of their WOLF Cell Sorter. The Series A investment was led by Ken Hood of San Diego’s FusionX Ventures, an early-stage investment fund. - February 08, 2016 - NanoCellect
Vivonics Sells Artificial Lung Technology
Vivonics, Inc. announced today the sale of intellectual property and other assets related to its Artificial Lung technology to Lung Biotechnology PBC, a wholly-owned subsidiary of United Therapeutics Corporation. Vivonics’ development of the Artificial Lung technology was supported by the... - February 04, 2016 - Vivonics, Inc.
Eminent Spine® Releases Updated King Cobra® White Paper
After receiving positive feedback from the cervical spine research community at last month’s CSRS meeting, Dr. Stephen Courtney has released the clinical results of his experience with two revolutionary cervical fusion devices. The King Cobra anterior cervical plate and the Copperhead... - February 02, 2016 - Eminent Spine
Coalition Forms to Study Medication Risk in Workforce Populations
Tabula Rasa HealthCare and The Greater Philadelphia Business Coalition on Health have partnered to examine the extent of medication risk in a diverse workforce population and the opportunities to mitigate that risk for the benefit of improving the health and welfare of employees and reducing unnecessary health care costs. - February 01, 2016 - Tabula Rasa HealthCare
International Equipment Trading Ltd. Relocates to Larger Office & Warehouse
International Equipment Trading Ltd.. (IET) recently moved its corporate headquarters to Mundelein, IL. The new office is approximately five miles from its previous location in Vernon Hills, IL. - January 30, 2016 - IET
ALPCO's New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time by Up to 86%
ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step, allowing labs to improve sample processing time by up to 86%. - January 26, 2016 - ALPCO
Reilly H. Stewart Recognized as a Professional of the Year by Strathmore's Who's Who Worldwide Publication
Reilly H. Stewart of Indio, California was recognized as a Professional of the Year for 2015 by Strathmore’s Who’s Who Worldwide for his outstanding contributions and achievements in the field of healthcare. About Reilly H. Stewart Mr. Stewart has almost 40 years experience in the... - January 14, 2016 - Strathmore Worldwide
New Frontier Partners with Aunt Zelda’s to Create a New Way to Prescribe Cannabis
New Frontier, the leading Big Data provider in the cannabis industry, is announcing a new strategic partnership with Aunt Zelda's, led by Mara Gordon, who has become the leading expert in alleviating patient suffering through the use of medical cannabis. Now, together with New Frontier, Aunt... - January 14, 2016 - Aunt Zelda's Inc
Drug Safety Company Expands Operations
Drug Safety Navigator, LLC (DSN) Announces Another Expansion in Its Fifth Year of Operation - January 13, 2016 - Drug Safety Navigator, LLC
Dr. Ashleigh Levison Joins Retinal Consultants of Arizona
Retinal Consultants of Arizona (RCA) – one of the nation’s leading Retina & Vitreous clinical research and patient treatment facilities – welcomes Dr. Ashleigh Levison to its team of world-class ophthalmologists specializing in diseases of the retina, vitreous and macula. Dr. - January 12, 2016 - Retinal Consultants of Arizona
BÜHLMANN Laboratories Opens North American Affiliate
BÜHLMANN Laboratories is proud to announce the availability of its products directly from its new North American affiliate, BUHLMANN Diagnostics Corp (BDC) in Southern New Hampshire. - January 11, 2016 - BUHLMANN Diagnostics Corp
SMi’s Mastering Clinical Trial Documents Masterclass 2016 Now Open for Registration
It's time to make plans for 2016, so don't miss the chance to attend SMi’s upcoming pharma masterclass "Mastering Clinical Trial Documents" taking place on the 16th March 2016 in London. - January 10, 2016 - SAE Media Group
H2Biologics Licenses Worldwide, Exclusive Rights to Develop SD1-Granzyme B Drug Conjugate for Treatment of Mesothelin-Expressing Tumors
H2Biologics announced that it has been granted a worldwide, exclusive license by the Research Development Foundation (RDF) for the use of human granzyme B (GrB), a naturally occurring serine protease, in developing an immunoconjugate with a human single domain antibody (SD1) that targets... - December 31, 2015 - H2Biologics Inc.
Scientists Discover Link Between Sleep Gene and Blood Cancer Risk- PiscoMed's Journal AMOR
Disruptions in the circadian clock genes may affect tumor formation, according to a study published by the journal AMOR. - December 18, 2015 - PiscoMed Publishing Pte Ltd
VIRUN NutraBIOsciences Collaborates with Otwo Biotech Shenzhen; 6 New Patent Applications in 2015; Virun’s New Facility is High-Tech; New Webinar Takes a Look Inside
VIRUN continues its’ interstellar growth by working with Chinese company Otwo Biotech of Shenzhen to bring new highly concentrated EPA DHA Omega products to market. Six new patent applications added to an already robust holdings. Virun’s new facility in Pomona, CA. nears completion and boasts State of the Art, eco-friendly functionalism, that includes heightened spray drying capabilities. A Live, upcoming Webinar, Feb. 2016, showcasing an "Inside Look" into VIRUN manufacturing and R&D. - December 16, 2015 - VIRUN
Hemophilia Treatment ACE910 Bypasses Factor VIII Inhibitor in Affinity Biologicals Plasmas
Chugai Pharmaceutical's newly developed antibody ACE910 is a potential lifesaving treatment for Hemophilia A patients who have developed Factor VIII inhibitors. A first-in-human study (1) recently published by the American Society of Hematology indicates that ACE910 may be a safe and effective treatment for hemophilia A patients. - December 11, 2015 - Affinity Biologicals
Cancer Generics Market: Industry Trends, Growth, Manufacturing Process, Machinery Requirements, Incomes and Profits
This report provides an insight into the cancer generics market and the requirements to setup and run a cancer generic manufacturing plant (both tablets and injectables). Factors such as capital cost, raw material requirements, machinery requirements, incomes, expenditures, etc. have been thoroughly analysed in this report. - December 03, 2015 - IMARC Group
Product Spotlight: Introducing Factor V Coagulation Antibodies from Affinity Biologicals Inc.
The human heart is an amazing vessel that pumps blood throughout the body, but sometimes genetic mutations make it difficult for the cardiovascular system to function the way it should. Most people inherit the factor V protein gene, which promotes healthy blood clotting throughout the body. Unfortunately, some inherit the factor V Leiden gene, which does just the opposite and prevents blood from clotting normally. - November 30, 2015 - Affinity Biologicals
Uploads on Biomedical Authoring Platform F1000Workspace Exceed 1m References
One million references have been loaded on to F1000Workspace – a research collaboration, reference management and authoring platform for scientists – since it was launched just six months ago. F1000Workspace is a suite of tools designed to assist biomedical researchers when writing... - November 26, 2015 - Faculty of 1000
How California Became the Center of the Stem Cell Universe - And Why That Matters to You
When Don Reed's son Roman was paralyzed in a college football game, the two began a 21 year quest for cure-- not just for paralysis, but for all forms of "incurable" disease. Joining with Bob Klein, father of a diabetic son, the Reeds helped pass Proposition 71, the California Stem Cells for Research and Cures Act. What happened next was a quiet triumph, step-by-step progress toward the cure of diseases which have plagued mankind for millennia. - November 25, 2015 - Americans for Cures Foundation
CentraForce Health Expands Population Health Platform Data Through New Data Alliance with Nielsen Scarborough and Kantar Media
New Alliance dramatically increases the quality, quantity and applicability of locally sourced population health insights. - November 25, 2015 - CentraForce Health
Global Infusion Pumps and Accessories Market Was Valued at US$ 5,874.3 Million in 2014 and Expected to Grow at a CAGR of 5.0% from 2015 to 2019
According to the new report “Global Infusion Pumps & Accessories Market Assessment & Forecast, 2015-2019” by SA-Business Research & Consulting Group, North America leads the market for global infusion pumps and accessories with a share of 38.0% in 2014 that translated into revenues worth US$ 2,320.3 million. - November 22, 2015 - SA-BRC
BUHLMANN Laboratories Announces New, Direct US Affiliate
BÜHLMANN Laboratories is proud to announce the establishment of its North American affiliate, BUHLMANN Diagnostics Corp (BDC) in Southern New Hampshire. - November 16, 2015 - BUHLMANN Diagnostics Corp
Rite Aid First U.S. Drugstore Chain to Offer Harmonyx Genetic Testing to Customers
Tests help determine most effective medication therapy based on an individual’s genetic makeup - November 12, 2015 - Harmonyx Diagnostics
Four Broad Run Students Return from UCLA
Ashburn Teens volunteer for brain tumor research in Los Angeles to help UCLA, Cedars-Sinai and Children's Hospital Los Angeles. - November 12, 2015 - TBKF
The Scientific Journal Highlights ASAlaser’s Commitment in Research
The company from Vicenza, leader in the study and implementation of laser’s therapeutic solutions, celebrates the first 7 years of Energy for Health, a magazine devoted to physical therapy. - November 01, 2015 - ASA srl
RxGenesys, LLC. Validates Claims via Double Blind Independent Study by Princeton Consumer Research
RxGenesys Complete Skin Care System(R) Reduces Fine Lines and wrinkles by 56% and Improves Radiance, Elasticity and Moisture Levels After Eight Weeks. Watch the interview at: http://youtu.be/9RySXfUbm3s RxGenesys, a developer, manufacturer and marketer of state-of-the-art skin care, based on a... - October 30, 2015 - RxGenesys
The Human Microbiome: Scientists to Unveil Latest Disease Research on Functionality and the Next Step Towards Causation at San Diego Congress
Scientists from academia and research studying the human microbiome set to share their collective insight at the Human Microbiome Congress in San Diego, CA this February. - October 30, 2015 - Kisaco Research
Patricia A. Cleary Recognized as a Professional of the Year by Strathmore's Who's Who Worldwide Publication
Patricia A. Cleary of Arlington, Virginia has been recognized as a Professional of the Year for 2015 by Strathmore’s Who’s Who Worldwide for her outstanding contributions and achievements in the field of education. About Patricia A. Cleary Ms. Cleary has 50 years experience in the... - October 27, 2015 - Strathmore Worldwide
Voicebrook to Exhibit at the American Pathology Foundation and American Society for Clinical Pathology Annual Meeting
Company will demonstrate leading solution for Pathology reporting at 2015 event, “Beyond the Lab” - October 26, 2015 - Voicebrook, Inc.
F1000Research Celebrates Major Milestone with Publication of 1,000 Articles Since Launch
F1000Research, the open science publishing platform for life scientists which was launched in 2013, has reached a fitting milestone with the publication of its 1,000th article. - October 18, 2015 - Faculty of 1000
Local Charity Partners with the Los Angeles County Sheriff’s Department’s SWAT (SEB) to Help Kids
Local charity partners with the Los Angeles County Sheriff’s Department’s SWAT (SEB) for the 20th Annual SEB Mud Run Benefiting kids with Duchenne Muscular Dystrophy. Special Guest, Atticus Shaffer, “Brick” from The Middle. - October 15, 2015 - Peyton's Project
New Autism Center Removes Barriers to Accessing Therapy
ABA Therapy Provider to Open Antioch Autism Center. - October 15, 2015 - Trumpet Behavioral Health
Gensco Laboratories Supports World Arthritis Day on October 12, 2015
Gensco Laboratories, a specialty pharmaceutical company, has recently introduced a new transdermal prescription medication that provides rapid relief at the first sign of an acute gout flare, ColciGel®, indicated for the treatment and prophylaxis of acute gout flares in adults. ColciGel® is easy to apply directly on the site of pain and each bottle has Metered Dose Technology (MDose™) which dispenses the exact amount of transdermal medication. - October 12, 2015 - Gensco Labs
Recursion Pharma Receives Orphan Drug Designation for Hereditary Stroke Disorder
Recursion Pharmaceuticals, a drug discovery start-up company, announced receipt of an Orphan Drug Designation from the FDA for the use of Tempol for the treatment of Cerebral Cavernous Malformation, a hereditary stroke disease. Recursion expects this will be the first of many potential treatments identified using their proprietary drug discovery platform. - October 05, 2015 - Recursion Pharmaceuticals
Dr. Edward Paul to Speak at Harvard
Dr. Edward Paul will speak at the Global Thought-Leader Forum at Harvard on December 5, 2015. - October 03, 2015 - Paul Vision Institute